Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 10/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 10/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | IGFBP5 | P24593 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18320554 | 0.81 | KDM4E (0.44) | CSNK2A2CSNK2BDHODHALOX15KDM4E | |
| SCHEMBL5101954 | 0.80 | ALDH1A1 (0.46) | GPR35HIPK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5090085 | 0.80 | CSNK2A2 (0.40) | CSNK2A2CSNK2BCSNK2A1DHODHALOX15 | |
| SCHEMBL23198535 | 0.80 | ALDH1A1 (0.50) | KDM4E | |
| SCHEMBL31254231 | 0.80 | ALDH1A1 (0.50) | KDM4E | |
| SCHEMBL2775988 | 0.77 | ALOX15 (0.58) | GPR35ALOX15KDM4E | |
| SCHEMBL4789438 | 0.77 | HIPK2 (0.39) | HIPK2CSNK2A2CSNK2BCSNK2A1KDM4E | |
| SCHEMBL212070 | 0.77 | KDM4E (0.42) | GPR35HIPK2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5102002 | 0.76 | ALOX15 (0.66) | GPR35CSNK2A2CSNK2BCSNK2A1DHODH | |
| SCHEMBL21714196 | 0.76 | CSNK2A2 (0.52) | HIPK2CSNK2A2CSNK2BCSNK2A1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | GPC BIOTECH AG (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | ROCK2, ROCK1, RHOT2 | GPR35 419/4885HIPK2 82/4885CSNK2A2 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.